Pharmacologic treatment of emotional lability

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Emotional lability may be a part of the syndrome of pseudobulbar palsy. Here we report our experience with fluvoxamine, a selective serotonin reuptake inhibitor, used to treat 10 patients with emotional incontinence. Over a 7-month period, we studied and treated 10 consecutive patients (mean age, 61 ± 8 years) attending our department: four had amyotrophic lateral sclerosis (progressive bulbar palsy form), four had clinically definite multiple sclerosis, and two had had strokes. They were given a single evening dose (100 mg) of fluvoxamine. All 10 patients had >30 affective outbursts daily. It was observed that in 2 to 6 days, all the patients improved, the number of emotional outbursts dropping to none to five per day. This result suggests that the serotoninergic system may be implicated in emotional lability. The short latency of improvement we observed in our patients suggests that the mechanism of fluvoxamine for treating emotional lability differs from its mechanism for treating affective disorders.

Original languageEnglish
Pages (from-to)532-535
Number of pages4
JournalClinical Neuropharmacology
Volume19
Issue number6
Publication statusPublished - 1996

Fingerprint

Fluvoxamine
Pseudobulbar Palsy
Progressive Bulbar Palsy
Therapeutics
Serotonin Uptake Inhibitors
Amyotrophic Lateral Sclerosis
Mood Disorders
Multiple Sclerosis
Stroke

Keywords

  • Emotional lability
  • Fluvoxamine
  • Serotoninergic system

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacologic treatment of emotional lability. / Iannaccone, Sandro; Ferini-Strambi, Luigi.

In: Clinical Neuropharmacology, Vol. 19, No. 6, 1996, p. 532-535.

Research output: Contribution to journalArticle

@article{a5cb0c4bdbb143bba721b3abb4142afa,
title = "Pharmacologic treatment of emotional lability",
abstract = "Emotional lability may be a part of the syndrome of pseudobulbar palsy. Here we report our experience with fluvoxamine, a selective serotonin reuptake inhibitor, used to treat 10 patients with emotional incontinence. Over a 7-month period, we studied and treated 10 consecutive patients (mean age, 61 ± 8 years) attending our department: four had amyotrophic lateral sclerosis (progressive bulbar palsy form), four had clinically definite multiple sclerosis, and two had had strokes. They were given a single evening dose (100 mg) of fluvoxamine. All 10 patients had >30 affective outbursts daily. It was observed that in 2 to 6 days, all the patients improved, the number of emotional outbursts dropping to none to five per day. This result suggests that the serotoninergic system may be implicated in emotional lability. The short latency of improvement we observed in our patients suggests that the mechanism of fluvoxamine for treating emotional lability differs from its mechanism for treating affective disorders.",
keywords = "Emotional lability, Fluvoxamine, Serotoninergic system",
author = "Sandro Iannaccone and Luigi Ferini-Strambi",
year = "1996",
language = "English",
volume = "19",
pages = "532--535",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Pharmacologic treatment of emotional lability

AU - Iannaccone, Sandro

AU - Ferini-Strambi, Luigi

PY - 1996

Y1 - 1996

N2 - Emotional lability may be a part of the syndrome of pseudobulbar palsy. Here we report our experience with fluvoxamine, a selective serotonin reuptake inhibitor, used to treat 10 patients with emotional incontinence. Over a 7-month period, we studied and treated 10 consecutive patients (mean age, 61 ± 8 years) attending our department: four had amyotrophic lateral sclerosis (progressive bulbar palsy form), four had clinically definite multiple sclerosis, and two had had strokes. They were given a single evening dose (100 mg) of fluvoxamine. All 10 patients had >30 affective outbursts daily. It was observed that in 2 to 6 days, all the patients improved, the number of emotional outbursts dropping to none to five per day. This result suggests that the serotoninergic system may be implicated in emotional lability. The short latency of improvement we observed in our patients suggests that the mechanism of fluvoxamine for treating emotional lability differs from its mechanism for treating affective disorders.

AB - Emotional lability may be a part of the syndrome of pseudobulbar palsy. Here we report our experience with fluvoxamine, a selective serotonin reuptake inhibitor, used to treat 10 patients with emotional incontinence. Over a 7-month period, we studied and treated 10 consecutive patients (mean age, 61 ± 8 years) attending our department: four had amyotrophic lateral sclerosis (progressive bulbar palsy form), four had clinically definite multiple sclerosis, and two had had strokes. They were given a single evening dose (100 mg) of fluvoxamine. All 10 patients had >30 affective outbursts daily. It was observed that in 2 to 6 days, all the patients improved, the number of emotional outbursts dropping to none to five per day. This result suggests that the serotoninergic system may be implicated in emotional lability. The short latency of improvement we observed in our patients suggests that the mechanism of fluvoxamine for treating emotional lability differs from its mechanism for treating affective disorders.

KW - Emotional lability

KW - Fluvoxamine

KW - Serotoninergic system

UR - http://www.scopus.com/inward/record.url?scp=0029840502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029840502&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 532

EP - 535

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 6

ER -